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DETECTION OF THE FACTOR V LEIDEN MUTATION IN A 
NONSELECTED BLACK POPULATION. 
Paul S. Pottinger, Fridbjorn Sigurdsson, and Nancy Berliner, Section of 
Hematology, Department of Internal Medicine, Yale University School of 
Medicine, New Haven, CT. 
The purpose of this study was to determine the prevalence of the factor V 
Leiden mutation among black and non-black inpatients and outpatients at the 
Yale-New Haven Hospital. We had found no previous information on the 
prevalence of this mutation within the black population, although it had 
been predicted by some that the abnormality might be found predominantly 
in individuals of European extraction. Randomly selected blood samples 
were obtained from the Yale-New Haven Hospital hematology laboratory and 
ethnic background was determined from hospital records. In addition, we 
studied stored DNA samples from black individuals already available in the 
laboratory from previous population studies. Using previously described 
methods, genomic DNA was isolated and analyzed by PCR and restriction 
enzyme digestion to identify the factor V cleavage site gene associated with 
activated Protein C (APC) resistance. Results were obtained on 214 black 
individuals, of whom 3 (1.4%) were heterozygous for the Factor V Leiden 
mutation. The incidence of the mutation in a similarly selected group of 126 
non-black patients was 1.6%, yielding a relative risk of 0.88 (Fisher Exact two- 
tailed test, P=1.0000, 95% confidence interval 0.12 to 7.64). These results do 
not support the hypothesis of a difference between the prevalence of the 
Factor V Leiden mutation in the black and non-black populations studied. 
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Introduction 
Overview 
Today we have a solid understanding of the physiology of blood 
coagulation in normal, healthy subjects. The clotting cascade - that dreaded 
maze of arrows and roman numerals which students diligently memorize in 
anticipation of exams - appears in textbooks as a gospel of established fact, and 
there is little mystery to the process in which blood turns from liquid to solid 
when vessels are damaged. 
We know considerably less about the reasons why blood clots in 
apparently healthy tissue. Venous thromboembolism has presented clinicians 
with diagnostic and therapeutic challenges for generations. It is a common 
source of morbidity and mortality, with an annual incidence of approximately 
1 in 1,0002. However, its molecular cause is rarely identifiable. Inborn 
deficiencies of the natural anticoagulant factors - Protein C, Protein S, 
Antithrombin III - and dysfibrinogenemia can be found in 5-10% of patients 
with venous thrombosis.345 The majority remain idiopathic. 
This changed somewhat in 1993 and 1994, with the publication of a 
series of elegant papers that demonstrated the presence of a previously 
unknown mutation in the gene for factor V.714 This mutation quickly 
became known as "factor V Leiden," in honor of the city in the Netherlands 
where it was elucidated. Initial studies indicated that factor V Leiden was far 
more prevalent among the general population than dysfibrinogenemia or 
deficient Protein C, Protein S, or Antithrombin III combined. Factor V Leiden 
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was also found in many more patients with venous thrombosis than the 
previous disorders, so the wide gulf of "idiopathic hypercoagulation" was 
narrowed considerably by the identification of this mutation. 
However, these initial studies were conducted in northern Europe, and 
at that time it was not clear whether the mutation was present to the same 
extent in other ethnic groups - for instance, American blacks. Our study was 
designed to address this question. 
In order to place this experiment in its proper context, we should first 
consider the mutation's physiology and clinical significance. 
What is Factor V? 
Factor V was first described independently by Dr. Armand J. Quick in 
1943, and by Dr. Paul A. Owren in 1947.15 Quick noticed that the prothrombin 
time (PT) of plasma would increase after the sample was stored on a shelf for 
more than eight days.lh He found that the PT would then return to norma! if 
he added plasma from experimental animals to the stored sample. 
Prothrombin had been described since the early 1930s,17 and Quick recognized 
that this chemical in the donor animal's plasma might be responsible for the 
normalization of prothrombin time. To eliminate this possibility, he fed 
bishydroxycoumarin to the donor animals, which would inactivate their 
own prothrombin activity. Even then, the normalization of stored plasma's 
PT persisted. He therefore postulated the existence of a "labile factor" in the 
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plasma distinct from prothrombin, which was lost during storage, but which 
would foster clot formation in life. 
For Owren, the inspiration to consider the possibility of a new 
coagulation factor came in the form of a single patient, an unfortunate young 
woman with a lifelong tendency to bleed heavily.18 Her prolonged PT could 
be normalized with donated, prothrombin-depleted plasma. This led him to 
conclude that she had a deficiency of some compound which he called 
"proaccelerin," since it sped up the PT. Because four proteins involved in the 
clotting process had already been described, he referred to proaccelerin as the 
"fifth coagulation factor," synonymous with today's "factor V." 
The structure and function of Factor V have subsequently been well- 
described.19 23 Indeed, the gene for factor V has been mapped to chromosome 
one (lq21-25),24 and its DNA sequence was published more than a decade 
ago.23 A brief review of Factor V physiology and regulation will be helpful 
before describing the Leiden mutation. 
Factor V serves a crucial role in the clotting cascade. A linchpin at the 
intersection of the "intrinsic" and "extrinsic" pathways of coagulation, it 
functions as a potent pro-coagulant (see Figure 1). 
When vessels are injured, tissue factor becomes exposed, and interacts 
with factor VII, leading to the conversion of prothrombin into 
thrombin.1617 26 Thrombin then activates platelets, converts fibrinogen to 
fibrin, and activates factors V and VIII. Under normal conditions, factor V 
circulates in the bloodstream as a biologically inactive single chain 
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Figure 1. Schematic representation of the coagulation cascade. Inhibition reactions 
are indicated by dashed arrows. Notice that factors Va and Xa participate together 
in a reaction that is common to clotting that originates in either the intrinsic or ex¬ 
trinsic pathways, and thus are part of the "final common pathway." Adapted from 
Stieve-Martin EA, Lotspeich-Steininger CA, Koepke JA (eds): Clinical Hematology. 
Philadelphia, 1998, p.614. 
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glycoprotein with a molecular weight of 330,000.23 It remains in this 
"dormant" state until it comes in contact with either thrombin or activated 
factor X (factor Xa). Although thrombin activates factor V at a rate 
approximately 100 times faster than factor Xa, the latter probably serves a 
more important role in the early stages of coagulation, when little thrombin 
has yet been generated.27 Both of these enzymes cleave factor V into factor Va, 
a heterodimer whose heavy chain (Mr = 94,000) and light chain (Mr = 74,000) 
are bound non-covalently by Ca2+ ions.23 Once activated, factor Va binds to 
activated platelets and becomes a receptor and cofactor for factor Xa. When 
factor Xa binds to factor Va, they together form a cleavage enzyme called 
"prothrombinase." Prothrombinase breaks prothrombin into thrombin, 
which will in turn activate more factor V, a cycle leading to the rapid 
amplification of the clotting cascade.22 
Therefore, very small amounts of factor Va lead to tremendous 
acceleration of the formation of platelet-fibrin clots. Without factor Va, 
clotting happens at only a small fraction of its potential: complete 
prothrombinase breaks prothrombin into thrombin 103 times faster than 
factor Xa alone.28 
How is FactorV Regulated? 
Factor Va's action is kept under strict control by an elegant series of 
enzymatic interactions.282W30 Although thrombin serves to activate factor V in 
The plasma concentration of Factor V has been measured at approximately 10 mg/liter.26 
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damaged vessels, it has the opposite function in healthy ones, due to its 
interaction with a protein called thrombomodulin. Thrombomodulin is a 
multi-modular protein of 557 amino acids with a trans-membrane domain 
that anchors it to the luminal surface of arterial, capillary, venous, and 
lymphatic endothelial cells. It is found in highest concentration in the 
microcirculation, where the ratio of endothelial cell surface area to blood 
volume is 1,000 times that in the great vessels.2b 
Thrombomodulin protrudes from the vessel wall into the 
bloodstream, and functions as a receptor for thrombin. As thrombin 
circulates in the blood and enters capillaries, it binds to thrombomodulin. 
Once bound, thrombin no longer participates in clotting reactions; rather, it 
serves as an activator of another soluble protein called protein C. 
The first attempts to purify protein C took place in I960,1' and today its 
structure and function are understood on a molecular level. It is a vitamin 
K-dependent zymogen comprised of a heavy chain and a light chain, with a 
molecular weight of 62,000 kDa. When protein C contacts the thrombin that 
is bound to thrombomodulin, its heavy chain is cleaved at a specific site near 
the amino terminus. This reaction exposes a Serine protease domain on the 
protein C molecule, converting it into a powerful cleavage enzyme referred to 
as "activated protein C" (APC) (see Figure 2). The protease action of APC is 
specific for three sites on the heavy chain of the factor Va heterodimer: when 
APC encounters factor Va, it cleaves the peptide bonds of the heavy chain at 
those sites, rendering it inactive as a cofactor for factor Xa. This process is 
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enhanced by the presence of protein S, a co-factor for APC whose precise 
mechanism of action remains unclear, and by factor V itself (see Figure 3). 
In contrast, when protein C encounters thrombin not bound to 
thrombomodulin, its activation is 20,000 times less efficient. This serves to 
prevent the activation of protein C at sites of vascular injury, where there is 
an appropriately higher proportion of free, unbound thrombin, therefore 
allowing the pro-coagulant action of factor Va to predominate where it its 
needed. 
In summary, factor V serves as a potent pro-coagulant when activated 
by cleavage at a specific site by thrombin or factor Xa. Factor Va activity, in 
turn, is regulated by the specific proteolytic action of APC at three different 
sites. The activity of APC is in turn downregulated at sites of vascular 
endothelial damage, because activation of protein C is much slower in the 
presence of thrombin which is not bound to thrombomodulin. 
What is Factor V Leiden? 
In 1993 Dahlback et a l described the phenomenon of poor 
responsiveness to APC in some patients who experienced venous 
thrombosis.7 In this study, the activity of protein C was tested in vitro by 
adding APC to the reagents used to determine the partial thromboplastin 
time (PTT), a test of the intrinsic and the final common pathway of 
coagulation. Because APC serves as an anti-coagulant, its addition to this 
reaction would be expected to increase the PTT. By comparing the PTT with 
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Figure 2. Schematic representation of the activation of protein C. Thrombin 
(T) circulates in the blood until it binds with thrombomodulin (TM), protruding 
from the vascular endothelium. Once bound, thrombin is able to bind protein 
C (pC) and enzymatically expose its serine protease moiety, thus converting it 
into activated protein C (APC), which can participate in the activation of factor V. 
Adapted from Dahlback B: Inhertited thrombophilia: Resistance to activated 
protein C as a pathogenic factor of venous thromboembolism (review). 
Blood 85:607-14, 1995. 
Figure 3. Model of the process by which the heavy chain of activated factor V (fVa) 
is broken into its inactivated form (fVi) by the proteolytic action of activated protein 
C (APC), with its cofactors protein S (pS) and factor V (fV). Events are believed to 
take place on the surface of phospholipid membranes. Adapted from Dahlback B: 
Inhertited thrombophilia: Resistance to activated protein C as a pathogenic factor 
of venous thromboembolism (review). Blood 85:607-14, 1995. 
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and without the addition of APC, a patient's response to APC can be 
quantified as the ratio between the two assays. Dahlback et al identified an 
individual with a strong personal and family history of multiple venous 
thromboses, and tested him and his family members for APC resistance in 
this manner. Among nineteen subjects tested, fourteen were found to have 
only a minimal increase in the PTT, placing them below the fifth percentile of 
control values. In other words, their blood was resistant to the anti-coagulant 
effects of APC. This observation was repeated in other studies; APC resistance 
was demonstrated again in 64 of 301 patients with thrombosis,8 in 33% of 104 
consecutive patients with a personal history of thrombosis.14 The authors 
who first observed this phenomenon made the reasonable speculation that 
APC resistance might be explained by an inherited deficiency of some yet- 
undescribed cofactor for protein C. 
Alternatively, it was postulated that the defect might lie in the targets 
of APC: factor V or factor VIII. In a study conducted by a team in the 
Netherlands,8^ patients with deep vein thrombosis and APC resistance were 
identified. Linkage analysis between the APC resistance trait and 
polymorphisms of the genes for various clotting factors revealed that APC 
resistance segregated with factor V but not factor VIII or von Willebrand 
factor, and therefore factor V became the focus of investigation. These 
patients' DNA encoding for factor V was analyzed. Careful sequencing and 
RFLP revealed the presence of a previously-unknown missense mutation 
which converted guanine to adenine at nucleotide 1,691 in the factor V 
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sequence. This in turn leads to a change in the codon sequence such that an 
arginine residue is replaced by a glutamine residue (CGA for arginine is 
replaced by CAA for glutamine). Because this residue is found at one of the 
three critical sites for proteolysis by APC, and because glutamine's acidic side 
chain renders it resistant to cleavage by the APC serine protease, the activated 
form of factor V Leiden is inactivated by APC at a much decreased rate. 
Therefore, it remains able to potentiate the clotting cascade even under 
circumstances in which it would normally be inactivated. 
Clinical Significance of Factor V Leiden 
The robust pro-coagulant function of factor V Leiden leads to an 
increased risk of venous thrombosis for patients who carry it, particularly 
those with other identifiable risks for hypercoagulability. In the few years that 
have followed the elucidation of factor V Leiden, its implications for patients 
with a number of clinical conditions have been investigated, such as protein 
C deficiency. In order to determine whether factor V Leiden plays an 
additional role in thrombotic complications among patients known to have 
deficient protein C, Koeleman et al studied the segregation of the mutation 
and APC deficiency.31 Out of 48 symptomatic patients with protein C 
deficiency, they detected 9 (19%) with factor V Leiden. Furthermore, in six 
families studied, 31% of subjects with protein C deficiency developed 
thrombosis, and 13% of subjects with factor V Leiden developed thrombosis; 
however, 73% of subjects with both conditions developed thrombosis, a 
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statistically-significant increase in risk. Although heterozygous protein C 
deficiency is itself found in only 0.1-0.5% of healthy blood donors,32 these data 
suggest that it can have significant clinical implications when present in 
combination with factor V Leiden. 
Factor V Leiden also fosters thrombosis in patients with other, far more 
common risk factors. For example, this mutation has an important impact 
on patients who use oral contraceptive pills (OCPs). OCPs have been 
associated with as increased incidence of venous thrombosis since their first 
use in the 1960s: it has been calculated that the incidence of 
thromboembolism among fertile, healthy women who did not use OCPs was 
approximately one in 20,000, whereas this value increased to one in 3600 
among comparable women using the early generation of OCPs.33 An 
increased risk persists even among users of later-generation OCPs, and the 
presence of factor V Leiden appears to greatly compound this risk, as 
demonstrated by Vandenbroucke et al.M Their retrospective analysis focused 
on 155 consecutive premenopausal women, aged 15 to 49, who had developed 
deep venous thrombosis in the absence of other underlying diseases. When 
compared with 169 population controls, subjects who used OCPs were four 
times more likely to develop a DVT, and subjects who later tested positive for 
factor V Leiden were eight times more likely. Those who both took OCPs and 
had factor V Leiden had a relative risk of 34.7 for experiencing thrombosis (Cl 
7.8-154). These data, and other series that corroborated them,35 37 spurred a 
debate as to whether asymptomatic women should be screened for factor V 
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Leiden before beginning OCPs.38'39 Considering the fact that approximately 9.9 
million American women rely on oral contraception,40 this is no small 
question. To date, a consensus seems to have been reached that general 
screening is not indicated. Cost-benefit analysis suggests that testing all 
patients for factor V Leiden before prescribing OCPs would be prohibitively 
expensive,41 and should be reserved for those with a clear medical or family 
history of thrombosis. 
Cigarette smoking may be another risk factor for thrombosis that is 
exacerbated by the presence of factor V Leiden. Among 84 women age 18 to 44 
who experienced a first myocardial infarction (MI), 10% were heterozygous 
for factor V Leiden, as compared with 4% of 388 age-matched controls, 
yielding an overall odds ratio for the development of MI among factor V 
Leiden carriers versus non-carriers of 2.4 (95% Cl 1.0 to 5.9).42 Closer 
inspection revealed an interesting trend: the mutation had little effect among 
non-smokers, with an odds ratio for the development of Ml among non¬ 
smoking factor V Leiden carriers versus non-smoking non-carriers equal to 
1.1 (95% Cl 0.1 to 8.5). However, among smokers the presence of factor V 
Leiden was a significant additional risk factor, with an odds ratio of 3.6 (95% 
Cl 0.9 to 14.4), and a 32-fold increase in the risk of MI among smoking carriers 
versus non-smoking non-carriers. 
Links have also been established between factor V Leiden and the 
Budd-Chiari syndrome,43 44 childhood ischemic stroke,45 46 fetal loss and 
preeclampsia,47 retinal vein occlusion,48 and venous thromboembolism in 
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concert with hyperhomocysteinemia.49 Even when we ignore the mutation's 
synergistic effects with other identified risk factors, such as OCPs and protein 
C deficiency, the overall risks it poses are impressive. In the original Leiden 
thrombophilia study,8 301 patients with deep vein thrombosis were tested for 
APC resistance by modified PTT assay. 21% of these patients demonstrated 
APC resistance, as compared with 3% of control subjects. When the factor V 
Leiden mutation was identified the following year, those same APC resistant 
patients were tested for the presence of factor V Leiden: 47 were heterozygous 
and 6 were homozygous, as compared to three heterozygous controls.9 It was 
therefore predicted that heterozygotes are at 5- to 10-fold the risk of venous 
thrombosis of non-carriers, and that homozygotes are at a 50- to 100-fold 
risk.26 
The Question of Prevalence 
From the earliest investigations, factor V Leiden seemed to be 
surprisingly common, not only among patients suffering from venous 
thrombosis, but also among the general population. In the Leiden 
thrombophilia study,8 64 of 301 consecutive Dutch patients with venous 
thrombosis tested positive for factor V Leiden, as did 14 of 301 healthy 
controls, suggesting a prevalence of about 5%. Subsequent studies of the 
general population in various countries demonstrated a peak carrier 
frequency of 13.4% in Greece911 and 10.9% in Sweden,51 with prevalence in 
other European nations ranging from 2.7% in Italy50 to 6.8% in the United 
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Kingdom,52 for a cumulative European average prevalence of 5.4%,53 making 
factor V Leiden by far the most common identified hereditary risk for venous 
thrombosis.26 
But as of the summer of 1995, we found no information on the 
prevalence of this mutation in the American black population. One of the 
earliest studies of factor V Leiden reported its presence in one African 
American individual,10 but this observation was not quantified in a 
population-based study. It had been proposed in 1994 that a founder effect 
might be responsible for the mutation's high prevalence, because a 
disproportionate number of factor V Leiden carriers were also carriers for a 
marker allele: when digested with Hinil, the DNA from 96% of 53 factor V 
Leiden carriers also had a cytosine at nucleotide 2,298, whereas only 73% of 69 
non-carriers had this base pair (x2diff = 30.4, d.f. =1; P<0.001).° However, this 
analysis is not conclusive proof of a founder effect, nor does it serve as a 
guarantee of the mutation's absence among American blacks. Although the 
mutation's molecular nature was understood, and its clinical implications 
had begun to be quantified, its prevalence among American blacks remained 
unknown. 
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Statement of Purpose 
At the time our study was conducted. Factor V Leiden had recently 
been described as the most common identifiable genetic risk for venous 
thrombosis in Caucasian patients. However, we found no data on the 
mutation's prevalence among American blacks. Therefore, the purpose of 
this study was to determine the prevalence of the Factor V Leiden mutation 
among non-selected black and non-black inpatients and outpatients at the 
Yale-New Haven Hospital. Our null hypothesis was that the mutation would 
not be detected among black patients to the same degree that it was detected 
among non-black patients. 
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Methods 
Overview 
In this study we chose samples of blood from the YNHH clinical 
hematology laboratory, identified the samples by ethnicity, extracted DNA 
from the blood, amplified a pre-determined portion of the gene for Factor V 
using the polymerase chain reaction (PCR), digested that DNA with a 
restriction enzyme, and used the restriction fragment length polymorphism 
(RFLP) to determine the presence or absence of the Factor V Leiden mutation. 
The techniques used were adapted from those described by Bertina et al9 and 
Koeleman et al,31 and can be summarized as follows: 
CHOOSE BLOOD SAMPLES 
\7 
IDENTIFY BLOOD BY ETHNICITY 
V 
EXTRACT DNA FROM WHOLE BLOOD 
V 
AMPLIFY FACTOR V DNA CLEAVAGE SITE 
with PCR 
\7 
DIGEST PCR PRODUCT 
with Mnl-I 
\7 
DETERMINE PRESENCE OR ABSENCE 
of FACTOR V LEIDEN 
with AGAROSE GEL ELECTROPHORESIS 
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Preparation 
A proposal to conduct this study was submitted to the Yale University 
School of Medicine's Human Investigations Committee. Permission was 
granted to proceed, with the understanding that the identities of participants 
would remain secret. No study subjects would be aware of their 
participation, and none would be contacted at any time, regardless of 
individual results. 
The YNHH admissions staff agreed to provide access to computerized 
hospital records. The hematology laboratory staff agreed to provide access to 
stored blood samples. 
Dr. Berliner, Dr. Sigurdsson, and I agreed that this research would be 
conducted by me under their close supervision; unless otherwise indicated, I 
performed all of the hands-on work herein. 
Patient Selection 
Participants in this study were selected in one of two manners: 
A. The hospital's clinical hematology laboratory routinely refrigerates 
tubes of blood for one week after they are drawn and analyzed, and these 
"remnant" blood samples were made available to us. In order to identify 
these anonymous blood samples by ethnic background, I first used the 
hematology laboratory computer to generate a list in chronological order of 
inpatients and outpatients whose blood had been drawn for unspecified 
assays after twelve noon on the previous day. The ethnicities of these 

18 
individuals was then verified using the hospital admissions laboratory 
computer, because all patients at Yale are required upon admission to describe 
their own ethnicity by choosing from the following categories: white, black, 
Spanish-American, Asian, Pacific Islander, Native American, or other. With 
knowledge of the patients' ethnicities, I then returned to the hematology 
laboratory to select appropriate blood samples for our study. Appropriate 
samples were at least 2cc of liquid whole blood in intact EDTA-anticoagulated 
VacutainersR ("lavender-top tubes"). Over the course of several weeks, 180 
blood samples were obtained from patients who had described themselves as 
"black," and 188 from control patients who did not describe themselves as 
"black"(166 "white," 15 "Spanish-American," 3 "Asian," 4 "other"). 1 recorded 
the donors' ethnicities, and numbered these samples in the order in which 
they were processed. All subsequent products of DNA analysis were labeled 
and referred to by these unique study numbers. 
B. The research laboratory of Dr. Bernard Forget contains a bank of 
DNA from patients who have participated in unrelated population studies. 
Some of these are black patients who have been diagnosed with either 
hereditary spherocytosis or hereditary eliptocytosis. Their DNA was 
meticulously extracted by Dr. Forget's staff, using the "by hand" technique 
described below. Forty-five of these DNA concentrates were sampled under 
sterile technique, consecutively labeled, and included in the study group. 
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Extraction of DN A 
DNA was extracted from whole blood by one of two methods: 
OIAamp Protocol 
In order to process high numbers of samples in a shorter time, 1 used 
the "QIAamp Blood Kit," manufactured by Qiagen.' Blood was processed 
according to the instructions which came with the kit. Each of the following 
steps was performed in a sterile fashion. 
1) Blood in a lavender top (EDTA) tube was obtained from the YNHH clinical 
hematology laboratory, as described above. Blood was stored at 4°C until 
processed. 
2) To increase the yield of DNA from whole blood, white blood cells were 
separated by centrifugation to obtain a buffy coat. This was done by gently 
agitating the sample on an automated tilt table for five minutes, then 
withdrawing 1.5ml into a 1.7ml eppendorf tube, and spinning at 4500g for 20 
minutes. 
3) 200k of buffy coat was transferred into a new 1.7ml eppendorf tube. 
4) To the buffy coat was mixed with 25A. proteinase (either QIA Protease or 
generic Proteinase K at lOpg/ml) and 200?v buffer AL, and vortexed 
immediately for ten seconds. 
5) The sample was then incubated at 70°C for 10 minutes, either on a heating 
block or in a hot water bath. 
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6) The sample was then incubated at 95°C for an additional 15 minutes. This 
step was intended to deactivate the proteinase and kill any contaminating 
microbes. 
7) The tube cooled for approximately five minutes, and then 2107. 100% 
isopropyl alcohol was added. The solution was vortexed. 
8) The solution was transferred into a proprietary QiagenB filter “spin 
column." This column was then placed in a 2ml collecting tube. The column 
and collecting tube were spun together at full speed for one minute, sending 
the liquid contents of the solution into the tube, and leaving the DNA 
behind. 
9) The column and DNA were transferred to a clean collection tube. The 
used collection tube was discarded. 
10) The column was washed with 5007. proprietary Buffer AW. The tubes 
were spun at full speed for one minute, sending the buffer wash into the 
collection tube and leaving the DNA behind. 
11) The collection tube was discarded and replaced with a sterile one, again 
washed with 5007. proprietary Buffer AW. This time the tube was spun at 
full speed for two minutes. 
12) The used collection tube was discarded, and the column was transferred 
to a sterile 1.7ml eppendorf tube. 
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13) 200X T.E., preheated to 70°C, was added to the spin column. When spun at 
full speed for one minute, the T.E. carries the DNA residue with it into the 
collection tube. 
14) To verify that this process succeeded in extracting DNA, 7k of the 
DNA/T.E. solution was mixed with 3k of loading buffer containing marking 
dyes. Samples were then analyzed on a standard 1% agarose gel with 
ethidium bromide at lOOmv for approximately 30 minutes. If present, DNA 
would show up as a sharp, intense, high-molecular-weight band. 
15) DNA was stored in the short run at 4°C, and at -20°C once PCR analysis 
was complete (see below). 
Triton X Protocol 
Early in our study DNA from 24 subjects was extracted with the 
following method. 
1) Blood in a lavender top (EDTA) tube was obtained from the YNHH clinical 
hematology laboratory, as described above. Blood was stored at 4°C until 
processed. 
2) Triton X solution was prepared as follows: 
0.32 M Sucrose 
10 mM Tris HC1, pH 7.5 
5 mM MgCl2 
1% Triton X 100 
109.5 g/L 
10 cc/ L of 1 M Stock 
5 cc/L of 1 M Stock 
lOcc/L 
Solution was autoclaved and stored at 4°C. 
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3) 5 cc whole blood was transferred into a 50 ml conical tube. Tube was filled 
to 50 ml with Triton X solution precooled to 4°C, then mixed by gentle 
shaking. 
4) Mixture was spun at 1000 g for 10 minutes at 4°C. 
5) Supernatant was discarded. Nuclear pellet could then be frozen at -70°C 
and stored indefinitely. 
6) 1 liter of RSB solution as follows: 
1M Tris 10 ml 
5M NaCl 20 ml 
0.5M EDTA 20 ml 
10% SDS 50 ml 
H20 900 ml 
7) Nuclear pellet was resuspended in 5 ml RSB. 
8) Proteinase K was added at 200 jig/ml, and the solution was incubated 
overnight at 37°C. 
9) 2.5 ml phenol and 2.5 ml chloroform were added to the tube. Tube was 
agitated gently. After the formation of an aqueous-organic fluid level, the top 
layer was discarded. 
10) Step nine was repeated once. 
11) To achieve better purification, 5 ml chloroform was added to the tube. 
Tube was agitated gently. After the formation of an aqueous-organic fluid 
level, the top layer was discarded. 
12) Step eleven was repeated once. 
13) 0.5 ml 3 M NaOAc was added. 
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14) DNA was precipitated with 13 ml 100% EtOH. 
15) A plOOO pipetman was used to move precipitate into a fresh 1.7 ml 
eppendorf tube. 
16) Precipitate was washed with 70% EtOH, and allowed it to air dry. 
17) Precipitate was re-suspended in 1.5 ml T.E. 
18) To verify that this process succeeded in extracting DNA, 77. of the 
DNA/T.E. solution was mixed with 37. loading buffer containing marking 
dyes. I then ran this mixture on a standard 1% agarose gel with ethidium 
bromide at lOOmv for approximately 30 minutes. If present, DNA would 
show up as a sharp, intense, high-molecular-weight band. 
19) DNA was stored in the short run at 4°C, and at -20°C once PCR analysis 
was complete (see below). 
Amplification of Factor V APC cleavage site with PCR 
In order to determine whether the Factor V Leiden mutation was 
present or absent in a given subject's DNA, it was necessary to analyze the 
RFLP pattern of the DNA that encoded for the APC cleavage site. The first 
step in this analysis involved the amplification of that site via PCR, as 
follows: 
1) DNA primer oligonucleotide primers were synthesized. These primers 
were the same as those used by Bertina et a l9 in their analysis of the factor V 
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Leiden mutation. They served to amplify a segment of the gene for factor V 
that includes the APC cleavage site. 
The primers had the following sequence: 
3': CTTGAAGGAAATGCCCCATTA 
5': TGCCCAGTGCTTAACAAGACCA 
2) A master mix of ingredients for PCR was prepared according to the 
number of tubes to undergo the process. Each tube contained the following 
sterile ingredients: 
0.5X DNA (obtained from either the QIAamp protocol or the Triton X 
protocol outlined above). 
0.2 U / X Taq Polymerase 0.25X 
0.1pg/X 3'oligo IX 
0.1 qg/ X 5'oligo IX 
10X buffer 5X 
2 mM dNTPs 5X 
25 mM MgCL, 10X (This is equivalent to a 5mM solution.) 
H2Q_30 X 
52.75X Total Volume 
In addition to the tubes containing study DNA, one tube contained no DNA 
("negative control tube") and one tube contained DNA that had been 
amplified successfully on previous occasions ("positive control tube"). 
3) These tubes were subjected to PCR according to the following program: 
Denature at 91°C x 40 seconds 
Anneal at 60°C x 40 seconds 
Extend at 71°C x 1 minute 
Repeat x 30 cycles 
Extend at 71°C x 5 minutes 
Soak at 4°C until tubes are removed from machine 
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4) 6X PCR product was mixed with 2X loading buffer containing marking dyes 
and electrophoresed through a 1% agarose gel with ethidium bromide for 
approximately 20 minutes. A base-pair "ladder" of Hindlll and 0X174 was run 
in each gel to determine fragment length. If present, the APC cleavage site 
would appear as a band of 220 base pairs. 
5) If the negative control lane displayed any bands, the experiment was 
considered contaminated, and all PCR products were discarded. 
6) If no bands appeared in any lane, or if bands appeared with lengths other 
than 220 base pairs, the PCR products from that tube were considered 
contaminated, and were discarded. 
Analysis of PCR Products with RFLP 
RFLP analysis was performed in order to determine whether the patient's 
amplified DNA was wild-type or factor V Leiden. 
1) A master mix was prepared, and the PCR product was digested as follows: 
3X 10X BSA 
3X 10X Buffer (New England Biolabs buffer #2) 
0.5X Mnl-1 (New England Biolabs, Equivalent to 2.5 U) 
20A, H20 
4X. PCR product 
30.5X total volume. 
2) Tubes were spun briefly to move all fluid into the bottom. 
3) Tubes were then incubated at 37°C for two hours. 

26 
4) Digestion was visualized on 2% agarose gel as follows: 6X loading buffer 
containing marking dyes was added to each tube, and the whole volume of 
digestion (approximately 36X) was loaded into large wells in the gel. One lane 
was loaded with undigested PCR product (the “negative control"), and 
another was loaded with digested PCR product from a patient with known to 
have Factor V Leiden (the “positive control"). A base-pair “ladder" was made 
with HINDIII and 0X174 Electrophoresis was performed in TBE at 150 mv for 
approximately 30 minutes. 
5) The gel was visualized and photographed. 
6) The predicted sizes of the digested PCR products from patients with wild- 
type factor V DNA are 163, 67, and 37 base pairs. 
7) Because the factor V Leiden mutation destroys a restriction enzyme site 
within this fragment, the predicted sizes of the digested PCR products from 
patients with factor V Leiden DNA are 153 and 67 base pairs. Therefore, the 
difference between 153 base pairs and 67 base pairs was diagnostic for Factor V 
Leiden. (See Figure 4.) 
8) Any uncut DNA was found at 220 base pairs (matching the band found in 
the “negative control" lane). If 220 was the only band found in a lane, that 
digestion was considered a failure, and more PCR product was digested and 
visualized. 
Time Course 
This research was conducted in June, July, and August of 1995. 
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Figure 4. Appearance of an agarose gel slab after undergoing electrophoresis with 
the DNA products of our experiment. A base-pair "ladder"was used at left to gage 
the lengths of DNA fragments. Proper amplification of the factor V cleavage site 
region yielded a band of 220 base pairs, and a faint band at the bottom of the gel, 
representing oligonucleotides left over from the PCR process. After undergoing 
digestion with the Mnl-I restriction enzyme, three patterns were possible: DNA 
from patients with two wild-type copies of the factor V gene would appear as three 
bands at 116, 67, and 37 base pairs; if patients were heterozygous for factor V Leiden, 
a band of 153 base pairs would appear in addition to the three bands found in the 
wild-type DNA; in patients who were homozygous for factor V Leiden, only bands 
at 153 and 67 base pairs would be expected. 
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Results 
The blood of 188 anonymous patients who did not describe themselves 
as "black" was obtained and analyzed as described above. Of these samples, 
four became contaminated, 45 were not amplified successfully via PCR, and 
13 were not digested successfully with Mnl-I. Of the remaining 126 samples, 
124 were negative for the factor V Leiden mutation, two were heterozygous 
positive, and none was homozygous positive. 
The blood of 180 anonymous patients who described themselves as 
"black" was obtained and analyzed as described above. Of these samples, three 
became contaminated, five were not amplified successfully via PCR, and six 
were not digested successfully with Mnl-1. Of the remaining 166 samples, 165 
were negative for the factor V Leiden mutation, one was heterozygous 
positive, and none was homozygous positive. 
DNA from 49 patients who described themselves as "black" and had 
participated in unrelated studies was obtained from another laboratory and 
analyzed as described above. Of these samples, one was not digested 
successfully with Mnl-I. Of the remaining 48 samples, 46 were negative for 
the factor V Leiden mutation, two were heterozygous positive, and none was 
homozygous positive. 
In total, then, of the 214 samples from black patients that were analyzed 
successfully, three (1.4%) tested positive for the factor V Leiden mutation. By 
comparison, the prevalence of the mutation in 126 samples from non-black 
patients that were analyzed successfully was two (1.6%). 
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Therefore, the relative risk of carrying a single copy of the factor V Leiden 
Mutation is 0.88 (Fisher Exact two-tailed test, P = 1.0000, 95% confidence 
interval 0.12 to 7.64). (See Table 1.) 
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Table 1. Results were obtained for 214 Black individuals, of whom 3 (1.4%) 
were heterozygous for the Factor V Leiden mutation. By comparison, the 
prevalence of the mutation in a group of 126 non-Black patients selected in 
the same manner was 2 (1.6%), yielding a relative risk of 0.88 (Fisher Exact 
two-tailed test, 95% Cl 0.12 to 7.64, P = 1.0000). No patients were found to be 
homozygous for factor V Leiden. 
Statistical analysis was computed with Epi Info.c 
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Discussion 
These data do not support the hypothesis of a difference between the 
incidence of the factor V Leiden mutation in the black and non-black 
populations studied. Rather, the proportion of these populations that carries 
a single copy of the factor V Leiden allele is very close: 1.4% among blacks and 
1.6% among non-blacks, a difference that is not statistically significant. 
Other studies confirm approximately the same prevalence of factor V 
Leiden among American blacks. Dilley et al54 tested for the prevalence of this 
mutation in 93 non-selected blacks, and found one heterozygous carrier, 
equivalent to a prevalence of 1.1%. Hooper et al55 looked for the mutation 
among 76 blacks without a history of thrombosis, and found one 
heterozygote, for a prevalence of 1.4%. Austin et aD assayed 130 African- 
Americans, and found one who was heterozygous for factor V Leiden, for a 
prevalence of 0.8%. The largest study to date on prevalence of the mutation 
among African Americans was published by Ridker et al last year."7 In this 
experiment, blood samples from 1,608 men participating in the Physicians' 
Health Study and 2439 women participating in the Women's Health Study 
were assayed using techniques of PCR and RFLP similar to those used in our 
study. Subjects were free of myocardial infarction, stroke, or venous 
thrombosis at time of enrollment. Six-hundred and fifty of them described 
themselves as African-American; 1.23% tested positive for factor V Leiden. 
(See Table 2.) 
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Factor V Leiden Mutation 
Author (ref.) Location Yes No Carrier 
Prevalence 
95% Cl 
present study (1) New Haven 3 211 1.4% 0.12-7.64 
Dilley (54) Atlanta 1 92 1.1% * 
Hooper (55) Atlanta 1 75 1.4% 0.02-3.60 
Austin (56) Atlanta 1 129 0.8% 0.01-2.1 
Ridker (57) USA 8 642 1.2% 0.53-2.41 
Total 14 1,149 1.2% 
Table 2. Cumulative data from this and other studies of the prevalence of the 
factor V Leiden mutation in non-selected patients who described themselves 
as "black" or "African American." The total prevalence of 1.2% is close to the 
1.4% found in our study. 
However, our control data are not in agreement with the prevalence 
found in other studies. In the Ridker data, for instance, 2,468 participants 
described themselves as Caucasian; 128 tested heterozygous positive for factor 
V Leiden, and 2 tested homozygous positive, for a total carrier rate of 5.27% 
(95% Cl 4.42 to 6.22). This is significantly different from our carrier rate; even 
when only "white" controls are included, the carrier rate is 1.8% (110 subjects, 
2 heterozygous positive). We have no explanation for this discrepancy. 
As more information has become available on the mutation's 
prevalence in different ethnic groups around the world, persuasive 
Preliminary data published as an abstract at the 1995 annual conference of the American 
Society of Hematology. No statistical analysis performed. 
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hypotheses have been made regarding its evolutionary genetics. Reviews 
such as that by Rees53 compile evidence that points strongly to a single origin 
of the mutation, or "founder effect," with subsequent genetic mixing to 
explain the mutation's existence in the new and old world. For instance, 
studies of more than 550 individuals from Sub-Saharan Africa have revealed 
no carriers of factor V Leiden,53,58 a marked contrast from the prevalence in 
American blacks, which would be consistent with genetic mixing rather than 
separate de novo mutations in the old and new worlds. 
If we wanted to apply our data to the question of whether factor V 
Leiden is present in blacks because of the mixing of genetic information from 
Europe or because of a de novo mutation, we would require extensive genetic 
pedigrees from all participants. We have no pedigrees on any study 
participants, nor do we have precise information on their ethnic 
backgrounds; we might imagine that patients of African, African-American, 
Caribbean, or Latin heritage might describe themselves as "black." New 
Haven does have a considerable African-American population, so it is not 
unreasonable to postulate that the majority of patients who described 
themselves as "black" would also describe themselves as "African-American" 
if given that option. However, we cannot take that assumption for granted. 
So the question of where the factor V Leiden mutation came from is beyond 
the scope of this study. 
Nor was that our intention. The origins and population drift of factor 
V Leiden pose fascinating questions, but those were not our questions. 
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Regardless of how or when Factor V Leiden entered the black population of 
New Haven, our data show that it is present to a significant degree. 
How, then, do we use this knowledge to best serve our black patients? 
Does it make sense to seek the mutation in every black resident of New 
Haven? Apparently it does not. It has been estimated that the cost of 
preventing one thromboembolic death by screening a general population 
with a factor V Leiden prevalence of 2% would cost over $44 million.59 
Furthermore, anticoagulating all factor V Leiden carriers would probably do 
more harm than good, because the morbidity of lifelong warfarin therapy 
would surpass the inherent thrombotic risk of the mutation.'"0,61 On the other 
hand, it does not seem prudent or ethical to ignore these data. Some middle 
ground must be sought, in which individual patient risk factors are 
considered. Patients with factor V Leiden should be counseled as to the risk 
factors that it entails, as should their families. 
So far, the risk factors among black carriers seem to be the same as 
those in the non-black population. At the time we conducted this study, it 
was unknown whether the detection of factor V Leiden among African 
Americans would hold implications specific to that group. For instance, 
patients with sickle cell disease would seem to benefit from screening for 
factor V Leiden; because both conditions are associated with abnormal blood 
flow, a synergistic effect and propensity towards more crises might be 
predicted. Interestingly, this has not been demonstrated. Wright et al found 
only one carrier of factor V Leiden among 165 patients with steady-state sickle 
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cell disease.62 Kahn et al63 looked for factor V Leiden in 82 patients with 
either HgbSS, SC, or S-beta thalassemia, 19 of whom had a history of stroke. 
Only one of the patients without a history of stroke had factor V Leiden, for a 
carrier prevalence of 1.2%. Although such data do not implicate factor V 
Leiden in the genesis of sickle crises, they do not rule out such an interaction 
either. 
In the few years since its description there has been a boom in 
information about the mutation: a Medline' search today for the subject 
“factor V Leiden" yields more than 250 results, and there is every indication 
that the research will continue. And with good reason. In a sense, the story 
of factor V Leiden is emblematic of much genetic research in the 1990s: we can 
identify the molecular lesion, we can quantify the clinical risks it entails, but 
we cannot repair the DNA. Until that becomes possible, we are obligated to 
pursue the mutation's presence in patients with thrombophilia, and make 
treatment decisions based on individual risk factors. Our data indicate that 
factor V Leiden is a risk factor that should be considered in both black and 
non-black patients. 
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